BRD2抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using BRD2 mouse mAb against C6 (1) and Hela (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using BRD2 mouse mAb (green) and negative control (red).    

  
  

The BRD2 antibody is a crucial tool for studying the Bromodomain-containing protein 2 (BRD2), a member of the BET (bromodomain and extraterminal domain) family. BRD2 plays a pivotal role in epigenetic regulation by binding to acetylated lysine residues on histones via its tandem bromodomains, facilitating transcriptional activation or repression. It is involved in critical cellular processes, including cell cycle progression, chromatin remodeling, and immune response regulation. Dysregulation of BRD2 has been linked to cancers, neurological disorders, and inflammatory diseases, making it a therapeutic target of interest.

BRD2 antibodies are widely used in research to detect protein expression, localization, and interactions through techniques like Western blotting, immunofluorescence, immunohistochemistry, and chromatin immunoprecipitation (ChIP). These antibodies help elucidate BRD2's role in gene regulation, particularly its association with transcriptional elongation factors and mediators of oncogenic pathways (e.g., MYC). Commercially available BRD2 antibodies vary in specificity, with common hosts including rabbit and mouse. Researchers must validate antibodies using knockout controls or siRNA to ensure target specificity, as cross-reactivity with other BET family members (e.g., BRD3. BRD4) can occur. Applications extend to drug discovery, especially in evaluating BET inhibitors for cancer therapy. Proper experimental optimization, such as adjusting antibody dilution and fixation methods, is essential for reliable results.